Westfield Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.31M | Sell |
10,619
-409,165
| -97% | -$90.8M | 0.01% | 217 |
|
|
2025
Q4 | $95.9M | Buy |
419,784
+411,856
| +5,195% | +$93.8M | 0.4% | 74 |
|
|
2025
Q3 | $1.84M | Buy |
+7,928
| New | +$1.61M | 0.01% | 220 |
|
|
2025
Q1 | – | Sell |
-57,357
| Closed | -$10.2M | – | 246 |
|
|
2024
Q4 | $10.2M | Sell |
57,357
-576,393
| -91% | -$106M | 0.04% | 188 |
|
|
2024
Q3 | $125M | Sell |
633,750
-371,308
| -37% | -$69.3M | 0.57% | 49 |
|
|
2024
Q2 | $172M | Buy |
1,005,058
+117,879
| +13% | +$19.5M | 0.85% | 20 |
|
|
2024
Q1 | $162M | Buy |
887,179
+47,440
| +6% | +$8.18M | 0.85% | 23 |
|
|
2023
Q4 | $130M | Buy |
+839,739
| New | +$122M | 0.76% | 25 |
|
|
2023
Q2 | – | Sell |
-83,017
| Closed | -$13.2M | – | 228 |
|
|
2023
Q1 | $13.2M | Buy |
83,017
+288
| +0.3% | +$44K | 0.09% | 173 |
|
|
2022
Q4 | $13.4M | Buy |
82,729
+1,627
| +2% | +$249K | 0.1% | 171 |
|
|
2022
Q3 | $10.9M | Sell |
81,102
-590
| -0.7% | -$84.7K | 0.09% | 176 |
|
|
2022
Q2 | $12.5M | Sell |
81,692
-14,710
| -15% | -$2.25M | 0.1% | 178 |
|
|
2022
Q1 | $15.6M | Sell |
96,402
-975
| -1% | -$142K | 0.1% | 172 |
|
|
2021
Q4 | $13.2M | Sell |
97,377
-939
| -1% | -$111K | 0.08% | 178 |
|
|
2021
Q3 | $10.6M | Sell |
98,316
-3,295
| -3% | -$377K | 0.06% | 181 |
|
|
2021
Q2 | $11.4M | Sell |
101,611
-1,295,683
| -93% | -$146M | 0.07% | 185 |
|
|
2021
Q1 | $151M | Buy |
1,397,294
+8,675
| +0.6% | +$928K | 0.94% | 23 |
|
|
2020
Q4 | $149M | Buy |
+1,388,619
| New | +$133M | 0.88% | 27 |
|
|
2016
Q1 | – | Sell |
-35,375
| Closed | -$2.1M | – | 253 |
|
|
2015
Q4 | $2.1M | Sell |
35,375
-2,935,101
| -99% | -$169M | 0.01% | 234 |
|
|
2015
Q3 | $162M | Sell |
2,970,476
-1,528,173
| -34% | -$99.5M | 1.14% | 20 |
|
|
2015
Q2 | $302M | Buy |
4,498,649
+278,140
| +7% | +$18.2M | 1.84% | 5 |
|
|
2015
Q1 | $247M | Buy |
4,220,509
+923,695
| +28% | +$55.8M | 1.42% | 7 |
|
|
2014
Q4 | $216M | Sell |
3,296,814
-50,861
| -2% | -$3.21M | 1.27% | 10 |
|
|
2014
Q3 | $193M | Buy |
3,347,675
+611,870
| +22% | +$34M | 1.18% | 14 |
|
|
2014
Q2 | $154M | Buy |
2,735,805
+601,785
| +28% | +$31.6M | 0.92% | 28 |
|
|
2014
Q1 | $110M | Sell |
2,134,020
-757,482
| -26% | -$38.3M | 0.66% | 45 |
|
|
2013
Q4 | $153M | Buy |
2,891,502
+2,858,762
| +8,732% | +$141M | 0.9% | 33 |
|
|
2013
Q3 | $1.46M | Hold |
32,740
| – | – | 0.01% | 266 |
|
|
2013
Q2 | $1.35M | Buy |
+32,740
| New | +$1.43M | 0.01% | 272 |
|
Other funds holding ABBV
VCM
VPM
Westfield Capital Management's ABBV Position: Q1 2026 in Review
Westfield Capital Management reduced its AbbVie (ABBV) stake by 97% in Q1 2026, selling an estimated $90.8M and leaving 10,619 shares worth $2.31M. The position accounts for 0.01% of the portfolio, ranked #217.
Westfield Capital Management first reported a position in ABBV in Q2 2013 and has held it in 29 quarters since. The position peaked at $302M in Q2 2015. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Westfield Capital Management held 10,619 shares of AbbVie worth $2.31M as of Q1 2026.
- Westfield Capital Management sold 409,165 AbbVie shares in Q1 2026, an estimated $90.8M.
- AbbVie made up 0.01% of Westfield Capital Management's portfolio in Q1 2026, its #217 holding.
- Westfield Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 29 quarters since.
- Westfield Capital Management's AbbVie position peaked at $302M in Q2 2015.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Westfield Capital Management's 13F filing for Q1 2026, filed 11 May 2026.